Polyneuropathy Associated with Age of Starting the Transfusion and Serum Ferritin Level in Iranian Patients with Thalassemia Major and Intermedia

References

• Akif Yesilipek M. Stem cell transplantation in hemoglobinopathies. Hemoglobin. 2007;31(2):251–256.
   PubMed Web of Science ®Google Scholar
• Nemtsas P, Arnaoutoglou M, Perifanis V, et al. Neurological complications of β-thalassemia. Ann Hematol. 2015;94(8):1261–1265.
   PubMed Web of Science ®Google Scholar
• Origa R. β-Thalassemia. Genet Med. 2017;19(6):609–619.
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Abbasian S, Ghaffari K, et al. Prevalence of alloantibodies and autoantibodies in transfusion dependent thalassemia patients. Iran J Blood Cancer. 2016;8(3):80–85.
   Google Scholar
• McDowell LA, Kudaravalli P, Sticco KL. Iron overload. Blood. 2018;118(16):421–30.
   Google Scholar
• Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800(8):760–769.
   PubMed Web of Science ®Google Scholar
• Morales NP, Rodrat S, Piromkraipak P, et al. Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients. Biomed Pharmacother. 2022;145:112381.
   PubMed Web of Science ®Google Scholar
• Ginzburg Y, Rivella S. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood,. 2011;118(16):4321–4330.
   PubMed Web of Science ®Google Scholar
• Ward RJ, Dexter DT, Crichton RR. Iron, neuroinflammation and neurodegeneration. IJMS. 2022;23(13):7267.
   Google Scholar
• Reddy PS, Locke M, Badawy SM. A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia. Ann Med. 2022;54(1):326–342.
   PubMed Web of Science ®Google Scholar
• Bayhan T, Ünal Ş, Konuşkan B, et al. Assessment of peripheral neuropathy in patients with β-thalassemia via electrophysiological study: reevaluation in the era of iron chelators. Hemoglobin. 2018;42(2):113–116.
   PubMed Web of Science ®Google Scholar
• Wahidiyat PA, Yosia M, Sari TT. Comparison of deferiprone to deferasirox and deferoxamine to cardiac and hepatic T2* MRI in thalassemia patients: evidence-based case report. Acta Med Indones. 2018;50(2):168–176.
   PubMed Web of Science ®Google Scholar
• Keikhaei B, Farmani-Anooshe N, Bahadoram M, et al. An overview of complications associated with deferoxamine therapy in thalassemia. J Nephropharmacol. 2020;10(1):e05-e–e05.
   Google Scholar
• Taher A, El‐Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458–465.
   PubMed Web of Science ®Google Scholar
• Sawaya RA, Zahed L, Taher A. Peripheral neuropathy in thalassemia. Ann Saudi Med. 2006;26(5):358–363.
   PubMed Web of Science ®Google Scholar
• Awang MS, Abdullah JM, Abdullah MR, et al. Nerve conduction study among healthy Malays. The influence of age, height and body mass index on median, ulnar, common peroneal and sural nerves. The Malaysian Journal of Medical Sciences: MJMS. 2006;13(2):19.
   PubMedGoogle Scholar
• El-Tagui MH, Salama KM, El-Sabbagh MH, et al. Polyneuropathy Associated with Severe Iron Overload and Oxidative Stress in β-Thalassemia Patients. Indian J Hematol Blood Transfus. 2019;35(3):518–522.
   PubMed Web of Science ®Google Scholar
• Stamboulis E, Vlachou N, Drossou-Servou M, et al. Axonal sensorimotor neuropathy in patients with β-thalassaemia. J Neurol Neurosurg Psychiatry. 2004;75(10):1483–1486.
   PubMed Web of Science ®Google Scholar
• Khosravi A, Naderi M, Ardalani GF, et al. Evaluation of peripheral neuropathy and associated risk factors in patients with beta-thalasemia major. J Neurol Sci. 2017;381:612.
   Web of Science ®Google Scholar
• Wong V, Li A, Lee A. Neurophysiologic study of β-thalassemia patients. J Child Neurol. 1993;8(4):330–335.
   PubMed Web of Science ®Google Scholar
• Kardelen F, Tezcan G, Akcurin G, et al. Heart rate variability in patients with thalassemia major. Pediatr Cardiol. 2008;29(5):935–939.
   PubMed Web of Science ®Google Scholar
• Watterworth B, Wright TB. Diabetic peripheral neuropathy. Pain: Springer; 2019. p. 911–913.
   Google Scholar
• Teunissen L, Notermans N, Wokke J. Relationship between ischemia and neuropathy. Eur Neurol. 2000;44(1):1–7.
   PubMed Web of Science ®Google Scholar
• Sharma D, Brandow AM. Neuropathic pain in individuals with sickle cell disease. Neurosci Lett. 2020;714:134445.
   PubMed Web of Science ®Google Scholar
• Duque A, Mediano MFF, De Lorenzo A, et al. Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications. World J Diabetes. 2021;12(6):855–867.
   PubMed Web of Science ®Google Scholar
• Kaplan PW, Sutter R. Electroencephalography of autoimmune limbic encephalopathy. J Clin Neurophysiol. 2013;30(5):490–504.
   PubMed Web of Science ®Google Scholar
• Forrest KY, Maser RE, Pambianco G, et al. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes. 1997;46(4):665–670.
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350.
   PubMed Web of Science ®Google Scholar
• Meisinger C, Döring A, Thorand B, et al. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr. 2006;84(3):483–489.
   PubMed Web of Science ®Google Scholar
• Brandow AM, Farley RA, Panepinto JA. Neuropathic pain in patients with sickle cell disease. Pediatr Blood Cancer. 2014;61(3):512–517.
   PubMed Web of Science ®Google Scholar
• Bertfield DL, Jumma O, Pitceathly RD, et al. Copper deficiency: an unusual case of myelopathy with neuropathy. Ann Clin Biochem. 2008;45(Pt 4):434–435.
   PubMedGoogle Scholar
• Jomova K, Valko M. Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des. 2011;17(31):3460–3473.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869–873.
   PubMed Web of Science ®Google Scholar